UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 1, 2006
REPLIDYNE, INC.
(Exact Name of Registrant as Specified in Charter)
| |
|
|
| Delaware
|
|
84-1568247 |
| (State or other jurisdiction of
|
|
(I.R.S. Employer |
| incorporation or organization)
|
|
Identification No.) |
| |
|
|
| 1450 Infinite Drive,
|
|
80026 |
| Louisville, Colorado
|
|
(Zip Code) |
| (Address of principal executive offices) |
|
|
720-996-5500
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. Results of Operations and Financial Condition.
On August 1, 2006, Replidyne, Inc. issued a press release announcing its financial results for
the quarter ended June 30, 2006. A copy of the press release is furnished as Exhibit 99.1.
In accordance with General Instruction B.2. of Form 8-K, the information presented under this
Item 2.01 and attached as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, except as expressly set forth by
specific reference in such a filing.
Item 7.01 Regulation FD Disclosure.
In the attached press release furnished as Exhibit 99.1, Replidyne, Inc. also announced that
the underwriters of its initial public offering have elected to partially exercise their
over-allotment option to purchase an additional 506,000 shares of common stock.
In accordance with General Instruction B.2. of Form 8-K, the information presented under this
Item 7.01 and attached as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, except as expressly set forth by
specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
| |
|
|
99.1
|
|
Press release of Replidyne, Inc., dated August 1, 2006, entitled “Replidyne Announces Second Quarter Results”. |